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Abstract
Background: Migraine is a prevalent and disabling headache disorder that affects more than 1.04 billion individuals
world-wide. It can result in reduction in quality of life, increased disability, and high socio-economic burden.
Nevertheless, and despite the availability of evidence-based national and international guidelines, the management
of migraine patients often remains suboptimal, especially for chronic migraine (CM) patients.
Methods: My-LIFE anamnesis project surveyed 201 General practitioners (GPs) from 5 European countries (France,
Germany, Italy, Spain, and the UK) with the aim of understanding chronic migraine (CM) patients’ management in
the primary care setting.
Results: In our survey, GPs diagnosed episodic migraine (EM) more often than CM (87% vs 61%, p < 0.001). We
found that many CM patients were not properly managed or referred to specialists, in contrast to guidelines
recommendations. The main tools used by primary-care physicians included clinical interview, anamnesis guide,
and patient diary. Tools used at the first visit differed from those used at follow-up visits. Up to 82% of GPs
reported being responsible for management of patients diagnosed with disabling or CM and did not refer them to
a specialist. Even when the GP had reported referring CM patients to a specialist, 97% of them were responsible for
their follow-up. Moreover, the treatment prescribed, both acute and preventive, was not in accordance with local
and international recommendations. GPs reported that they evaluated the efficacy of the treatment prescribed
mainly through patient perception, and the frequency of follow-up visits was not clearly established in the primary
care setting. These results suggest that CM is underdiagnosed and undertreated; thereby its management is
suboptimal in the primary care.
Conclusions: There is a need of guidance in the primary care setting to both leverage the management of CM
patients and earlier referral to specialists, when appropriate.
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Referral, Prophylaxis
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Background
Headache disorders are a notable public health concern
and a significant cause of disability worldwide. Among
headache disorders, migraine is the main cause of recur-
rent headache (> 90%) [1], affecting 80.8 million individ-
uals in Western Europe, and more than 1.04 billion
world-wide [2]. Migraine impacts personal life but also
has significant socio-economic and public health-related
implications [3]. The Global Burden of Diseases, Injuries,
and Risk Factors (GBD) study reported that migraine
was responsible for 5.6% of all years lived with disability
(YLDs) in the world, and for 6.2% of YLDs in Western
Europe, and consider it to be the leading cause of dis-
ability in people 15–49 years old, accounting for 8.2% of
YLDs worldwide [4, 5]. Between 2.5–3.1% of people with
episodic migraine (EM) develop chronic migraine (CM)
within one year [6–8], which is defined by headache on
≥15 days per month for ≥3 months, of which at least 8
days/month have migraine headache features [9, 10].
CM is associated with substantially greater reduction in
quality of life and increased disability compared to EM,
resulting in even greater personal and socio-economic
burden [11–13].
Despite being highly prevalent and having significant
personal and social impact, migraine may not receive ap-
propriate attention, probably because it is not a life-
threatening disease and may result in invisible disability
and is common among the population. As a result, mi-
graine and particularly CM, is largely underdiagnosed
and undertreated worldwide [14, 15].
Migraine is a clinical diagnosis with primarily subject-
ive manifestations and there are no diagnostic tests ei-
ther for this condition or any of the primary headache
disorders, nor for secondary headache disorders such as
medication overuse headache (MOH). Thus, medical
history and anamnesis are crucial for proper diagnosis
[16]. Together with the medical history, the anamnesis
done by asking specific questions to the patient will pro-
vide the physician with useful information to formulate
the diagnosis. According to the International Classifica-
tion of Headache Disorders (ICHD) and European Head-
ache Federation (EHF), EM can be managed in primary
care, but CM requires specialist referral because diagno-
sis and, particularly, management can be difficult [9, 17].
Nevertheless, in the Eurolight study carried out in 10
European countries, 33.8% of patients reported frequent
migraine (> 5 days/month), of which < 18% had seen a
GP, and < 15% had visited a neurologist [15]. Moreover,
although 1/3 of patients reported frequent migraine and,
therefore, need of preventive medication, < 11% of pa-
tients were receiving adequate acute treatment, and even
a lower proportion (< 6.4%) were receiving preventive
medication [15]. An observational study on the use of
antimigraine treatments by French GPs identified that
acute headache treatment is prescribed according to na-
tional practice guidelines and is considered as effective
and satisfactory. In contrast, it showed that the use of
preventive medication is low [18].
Considering the low proportion of people consulting
GP and migraine specialists, and the mishandling re-
ported of the acute and preventive treatments, it is cru-
cial to better understand management of CM patients in
the primary care setting. Thus, the aim of the My-LIFE
anamnesis project was to describe the real current clin-
ical practice regarding disabling and CM identification,
treatment, and referral in the primary care setting in 5
European countries (France, Germany, Italy, Spain, and
the UK).
Methods
My-LIFE anamnesis project was designed as a survey to
GPs from 5 European countries: France, Germany, Italy,
Spain, and the UK using a structured online
questionnaire.
The project involved two sets of participants: members
of the Steering Committee (SC), and survey participants.
The Pan-European SC included 7 members, well known
clinical experts in migraine from Germany, Italy,
Norway, Russia, Spain, Switzerland, and the UK. Their
roles included performing literature reviews, defining the
key objectives and the main content of the online ques-
tionnaire, and data interpretation.
For the survey, GPs from 5 European countries
(France, Germany, Italy, Spain, and the UK) were invited
to participate. In order to secure that participants had
some background in the diagnosis and management of
headache disorders the following selection criteria were
defined: i) with at least 2 years of experience in general
practice; ii) who were seeing at least 5 patients suffering
from headache disorders per week; iii) usually proceeded
with the medical history of their patients with headache
disorders; iv) had currently at least 1 patient suffering
from episodic and/or CM.
Ethics Committee approval was not applicable in this
survey because its objective was to understand chronic
migraine patients’ management in the primary care set-
ting. There was no need to collect any type of patient
data or information, hence the approval of an Ethics
Committee or patient informed consent was not re-
quired. All survey participants gave their written
consent.
Questionnaire
Development of the questionnaire was based on a litera-
ture search and on the clinical experience of the SC
members. The 32-item questionnaire was divided in
three main sections: Participants’ profile; Current clinical
practice in disabling or CM identification and treatment;
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and Definition of a Migraine Anamnesis Guide (Add-
itional file 1). The questionnaire was written in English
and translated into local languages (French, German,
Italian, and Spanish). It was administered to 201 GPs
fulfilling the inclusion criteria between 14th January
2020 and 28th January 2020 through an online platform
that ensured data anonymity and confidentiality as well
as that all questions were answered in order to avoid any
missing value.
Statistical analysis
Categorical variables were expressed in terms of means
and standard deviations (SD) or range, or number and
percentage of responses. Comparative analysis among
countries was carried out with Chi-square test or
ANOVA test for categorical and continuous variables,
respectively. Data analysis was performed with the SPSS




In the My-LIFE anamnesis project, 201 GPs from 5
European countries were included: 41 GPs from France,
and 40 GPs each from Germany, Italy, Spain, and the
United Kingdom. GPs had 24 (range 2–42) years of ex-
perience and each saw 202 patients per week, on aver-
age. Twelve percent of patients presented with headache
disorders, and migraine was diagnosed in 38% of them.
Among migraine patients, 66% presented with EM, and
34% with CM (Additional file 2).
Headache diagnosis
When the participants were asked about who did the
diagnosis of EM or CM of their patients, the proportion
of diagnosis ascertained by GP versus specialist signifi-
cantly differed between EM (87% GP vs 13% specialist)
and CM (61% GP vs 39% specialist) (p < 0.001). For EM
diagnosis, no differences between countries were found;
however, for CM significant differences (p = 0.015) were
observed, ranging from 81% in France to 45% in Italy
(Table 1).
Headache disorders to be managed at primary care in-
clude tension-type headache (TTH), MOH and migraine
[9], and GPs were asked about the differential diagnosis
of these conditions. During the anamnesis of a patient
with a headache disorder, 61% of participants always
considered TTH, and 57% always ruled out MOH, but
significant differences were observed among countries:
80% of UK GPs and 78% of Spanish GPs always ruled
out TTH vs. 38% of Italian GPs. Consideration of MOH
varied from 85% in the UK to 30% in Italy (p < 0.001, for
both comparisons) (Table 1).
There are several instruments available to aid
primary-care physicians in both migraine diagnosis
and management. In our survey, the tools used to as-
sess patients with disabling and CM at the first visit
differed from those used in the follow-up visits. At
the first visit, all participants (100%) conducted a clin-
ical interview (vs. 51% at follow-up visits, p < 0.001),
and 46% of them used an anamnesis guide (a guide
to support the physician during the diagnosis) to
diagnose CM (vs. 26% at follow-up visits, p < 0.001).
In contrast, patient diaries were more often used at
follow-up visits (69% vs. 36% at the first visit, p <
0.001), and also imaging techniques (50% vs. 21% at
the first visit, p < 0.001).
Validated scales to assess the impact of migraine and
validated migraine screening tools were used by less
than 35% of the participants at both the first and follow-
up visits (Fig. 1a).
When considering the tools used by country in the
first visit, significant differences were observed in patient
diary use (p = 0.025), imaging techniques (p = 0.021), and
validated scales to assess the impact of migraine (p =
0.006) (Fig. 1b).
Anamnesis guide characteristics
Sixty-four percent of participants reported using an an-
amnesis guide to diagnose CM at any time. The guides
used were heterogeneous, either developed by them-
selves (41%) or by the centre where the GP worked
(15%), or validated and published guides (44%). Spain
and Italy had the highest percentage of GPs using a vali-
dated and published anamnesis guide (54 and 52%, re-
spectively) (p = 0.012) (Table 2).
Inclusion of red flags i.e., signs or symptoms that can
guide successive investigations and/or referral and
decision-making, is common in primary care manage-
ment of migraine. On average, 60% of the anamnesis
guides used by GPs included red flags/warning features.
Up to 93% of the anamnesis guides used in the UK and
89% in Spain included red flags vs. 19% in Italy (p <
0.001) (Table 2). There was no statistical difference be-
tween the anamnesis guide type used and the inclusion
of red flags.
The main topics addressed during the anamnesis in-
cluded frequency of attacks; medication use, fre-
quency and effectiveness; and pain characteristics of
the attacks, among others. These topics were inde-
pendent of the anamnesis guide type used, and they
were also independent of whether or not an anam-
nesis guide was used. However, when an anamnesis
guide was not used, there was a trend to ask fewer
questions and more differences between countries
were found regarding the topics asked.
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Fig. 1 Tools used to assess patients with disabling or chronic migraine. a. Tools used at the first visit vs. tools used at the follow up visit (total). At
the first visit,” others” included review of the medication and clinical examination including blood pressure; physical examination, and blood test.
At the follow-up visit, “others” included physical examination, blood test, pain using a VAS, and patient information leaflets. *p < 0.05. b. Tools
used at the first visit, by country. *p < 0.05





















Episodic migraine Done by GP 175 (87.1%) 38 (92.7%) 33 (82.5%) 30 (75.0%) 37 (92.5%) 37 (92.5%) NS
Done by a specialist 26 (12.9%) 3 (7.3%) 7 (17.5%) 10 (25.0%) 3 (7.5%) 3 (7.5%)
Chronic migraine Done by GP 123 (61.2%) 33 (80.5%) 21 (52.5%) 18 (45.0%) 26 (65.0%) 25 (62.5%) < 0.05
Done by a specialist 78 (38.8%) 8 (19.5%) 19 (47.5%) 22 (55.0%) 14 (35.0%) 15 (37.5%)
DIFFERENTIAL DIAGNOSIS
TTH rule-out Always 122 (60.7%) 21 (51.2%) 23 (57.5%) 15 (37.5%) 31 (77.5%) 32 (80.0%) < 0.05
Sometimes 59 (29.3%) 11 (26.8%) 17 (42.5%) 15 (37.5%) 8 (20.0%) 8 (20.0%)
Never 20 (10.0%) 9 (22.0%) 0 (0.0%) 10 (25.0%) 1 (2.5%) 0 (0.0%)
MOH rule-out Always 115 (57.2%) 17 (41.5%) 25 (62.5%) 12 (30.0%) 27 (67.5%) 34 (85.0%) < 0.05
Sometimes 72 (35.8%) 17 (41.5%) 14 (35.0%) 23 (57.5%) 12 (30.0%) 6 (15.0%)
Never 14 (7.0%) 7 (17.0%) 1 (2.5%) 5 (12.5%) 1 (2.5%) 0 (0.0%)
MOH medication-overuse headache, NS non-significant, TTH tension-type headache
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Patient diary characteristics
Overall, 85% of participant GPs asked the patient to
complete a patient diary, headache diary or calendar at
any time. Most of the participants (62%) recommended
recording some items on a notebook used as a patient
diary instead of using a formal headache diary or calen-
dar, and 38% recommended either a standard diary or a
validated/published tool, without differences among
countries. The main items requested to be recorded
were frequency (96%) and duration (91%) of the attack,
followed by medication taken and intensity of the head-
ache (Fig. 2). It is noteworthy that, when using a vali-
dated/standard patient diary, information was more
consistent and comprehensive, and more items were re-
corded, with statistically significant differences regarding
the headache characteristics (p = 0.005) and intensity
(p = 0.001).
Other diagnostic tools
Up to 50% of GPs used imaging techniques at follow-up
visits to assess patients with disabling or CM (Fig. 1a). In
this context, 58% of GPs stated that imaging techniques
were mainly used to rule out secondary headache disor-
ders. Besides, around 48% of the participants used vali-
dated scales to assess patients with migraine at any time.
Among these, ID-Migraine was the most used in the first
visit (63% of participants, p < 0.001) (Fig. 3a), while ID-
Chronic migraine (ID-CM) (32%) and Headache Under-
Response to Treatment (HURT) scales (31%, p = 0.003)
were the most used validated scales in the follow-up
visit. The ID-CM scale was employed by up to 59% of
Italian GPs at the first visit (p = 0.013) (Fig. 3b).
Chronic migraine management by GPs
Overall, 82% of GPs reported that they usually managed
patients diagnosed with disabling or CM themselves,
without referral to a migraine specialist. Among these
GPs, 82% reported prescription of acute medication
and 72% of migraine preventive treatment when
needed, with significant differences among countries
for both acute (p < 0.001) and preventive treatment
(p = 0.003). Up to 94% in Germany and 95% in France
Table 2 Characteristics of anamnesis guides used by GPs
ANAMNESIS GUIDE
CHARACTERISTICS
Total (n = 128)
n (%)
France (n = 25)
n (%)
Germany (n = 23)
n (%)
Italy (n = 27)
n (%)
Spain (n = 26)
n (%)
UK (n = 27)
n (%)
p value
Anamnesis guide type < 0.050
Anamnesis guide validated
and published (n = 56)
56 (43.8%) 8 (32.0%) 10 (43.5%) 14 (51.9%) 14 (53.8%) 10 (37.0%)
Anamnesis guide developed
by the centre where the
responder works (n = 19)
19 (14.8%) 1 (4.0%) 1 (4.3%) 3 (11.1%) 8 (30.8%) 6 (22.2%)
Guide/document developed
by the respondent (n = 53)
53 (41.4%) 16 (64.0%) 12 (52.2%) 10 (37.0%) 4 (15.4%) 11 (40.7%)
Inclusion of red flags 77 (60.2%) 12 (48.0%) 12 (52.2%) 5 (18.5%) 23 (88.5%) 25 (92.6%) < 0.050
Fig. 2 Main items recorded in the patient diary. *p < 0.05
Ryvlin et al. BMC Neurology            (2021) 21:1 Page 5 of 11
Fig. 3 Validated scales used as diagnostic tools in patients with disabling or chronic migraine. a Validated scales used in the first visit vs. follow-
up visit (total). *p < 0.050. b. Validated scales used by country in the first visit. *p < 0.050. †Other scales used with the patients with disabling or
chronic migraine include KIEL HD questionnaire, Migraine Specific Quality of Life, and QVM score (Qualité de Vie et Migraine). HALT, Headache-
Attributed Lost Time index. HIT-6, Headache Impact Test. HURT, Headache Under-Response to Treatment Questionnaire. MAT, Migraine
Assessment Tool. MIDAS, Migraine Disability Assessment Score
Fig. 4 Treatments prescribed to disabling or CM patients by GPs, when not referring the patient
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prescribed acute medication, and in the UK, 94% of the
patients were prescribed preventive treatment (Fig. 4).
There were no differences between countries, either in
the percentage of patients prescribed acute medication
prescribed or the percentage of patients prescribed pre-
ventive treatment.
Besides, GPs who reported that they were in charge of
the treatment of CM patients considered that main rea-
sons for referring patients include diagnostic uncer-
tainty, lack of response to preventive or acute treatment,
and or highly disabling migraine. Some differences were
observed between countries: diagnostic uncertainty
(p = 0.036), highly disabling migraine (p = 0.013), lack
of response to preventive (p = 0.008) or acute treat-
ment (p = 0.003).
Chronic migraine patients’ referral and follow-up
Eighteen percent of the GPs reported that they “usually
referred patients diagnosed with disabling or CM to a
migraine specialist”. Among them, 76% mentioned that
the main reason for referral was diagnostic confirmation
(Fig. 5). In all countries 80–100% of GPs mentioned
diagnostic confirmation as the main reason for referral,
with the exception of only 29% in Spain (p = 0.022). In
Germany, 83% of the participants referred their patients
to give them access to a preventive treatment (p =
0.038); whereas preventive treatment access was not a
strong reason for referral in Italy (19%) or in the UK
(17%) (Fig. 5).
Even when the GP reported referring CM patients to a
specialist for treatment prescription, up to 97% of GPs
were in charge of ongoing management of most patients.
The evaluation of the efficacy of the treatment pre-
scribed by the specialists was mainly done through the
patient perception (72%). Although non-significant,
Spain was the only country where the ongoing evalu-
ation was mainly done through a patient diary (86%).
Moreover, the frequency of the treatment efficacy evalu-
ation was not clearly established in the primary care set-
ting, since yearly, semester, quarterly, monthly basis, and
as needed evaluation were performed equally. To note,
all French participants reported weekly evaluation of
treatment efficacy (Table 3).
In contrast, among GPs that usually treated CM pa-
tients themselves, the main indicators to evaluate the ef-
ficacy of acute and preventive treatments was the patient
perception of the treatment (75%), and the frequency of
the migraine attacks. On average, efficacy of the pre-
scribed acute treatment was evaluated on a monthly
basis by 50% of the participants. Of note, 10% of GPs
evaluated the efficacy when the patient came back with
complaints, without significant differences between
countries (Table 3). The efficacy of the prescribed
preventive treatment was evaluated on a monthly or
quarterly basis by 81% of GPs on average. In the UK,
Germany and Spain, 15–17% of GPs evaluated treatment
efficacy when the patient came back complaining, while
no GP reported this in Italy and France. In France up to
22% of GPs evaluated treatment efficacy on a weekly
basis (p = 0.002) (Table 3). A small percentage of the
participants used validated scales to evaluate the efficacy
of treatment (acute or preventive) (Table 3); however,
when the patient was referred and the GP was only in
charge of follow up, GPs did not use validated scales.
Discussion
The outcomes of this project provide data on the diag-
nosis and management of CM from 201 randomly se-
lected GPs from 5 European countries, that could reflect
what is currently being done in the primary setting with
Fig. 5 Reasons for referral of patients with disabling or chronic migraine, by country. *p < 0.050
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regards to HD disorders management. The main results
from this survey suggest that many patients are under-
diagnosed and undertreated. Most patients are not re-
ferred to specialists, and treatments prescribed, both
acute and preventive, are not in accordance with local
and international recommendations being the manage-
ment of CM patients clearly suboptimal.
CM affects approximately 2% of the world population
[19] and up to 4% of the European individuals [20]. Des-
pite being an uncommon headache disorders, entails sig-
nificant burden and should be recognized in primary
care [9, 10], and this study indicates the need of in-
creased awareness of CM. In the present survey, we
found that 61% of CM diagnosis was made by GPs. Con-
sidering that diagnosis of migraine and CM is made
solely through a proper anamnesis, the percentage of
GPs that proceeded with a clinical interview in the
follow-up visit (51%) is low. This may be explained by
the limited time that can be dedicated to the patients in
the primary care setting. According to guidelines [9],
migraine diagnosis should include differential diagno-
sis of MOH and TTH, but only 61% of participants
always ruled out TTH and 57% MOH. MOH requires
an underlying primary headache disorder (most
commonly migraine) and up to 2/3 of CM patients
present with MOH [21]. The presence of MOH may
complicate CM diagnosis, and even if MOH is con-
comitant with CM, it must be recognized and managed
independently [9, 10, 17].
Proper management of migraine and other headache
disorders requires continued monitoring of symptoms
over time. For symptom monitoring in primary care, pa-
tient diaries are recommended because they can help to
monitor headache intensity and frequency of symptoms
[9, 10]. A positive finding from our survey was that al-
most 70% of participants reported the use of diaries in
the follow-up visits.
In the follow-up visits imaging techniques were re-
ported to be used by 50% of participants suggesting that
CM patients are being submitted to imaging techniques
too often, increasing the cost of CM patients manage-
ment of the health care systems; however, current guide-
lines state that patients with headache and a normal
neurological examination have the same the risk as the
normal population of serious secondary pathology find-
ings in neuroimaging [17, 22, 23]. Neuroimaging is not
indicated unless the history or examination suggests
headache may be secondary to another condition [9];
Table 3 Evaluation of the efficacy of the treatment when the patient is not referred
ACUTE TREATMENT
(n = 134)
Total (n = 134)
n (%)
France (n = 37)
n (%)
Germany (n = 32)
n (%)
Italy (n = 19)
n (%)
Spain (n = 26)
n (%)
UK (n = 20)
n (%)
p value
Evaluation of efficacy NS
Patient perception 100 (74.6%) 30 (81.1%) 23 (71.9%) 14 (73.7%) 17 (65.4%) 16 (80.0%)
Patient diary 81 (60.4%) 21 (56.8%) 20 (62.5%) 12 (63.2%) 19 (73.1%) 9 (45.0%)
Validated scale 16 (11.9%) 3 (8.1%) 4 (12.5%) 2 (10.5%) 23 (23.1%) 1 (5.0%)
Frequency of evaluation of efficacy NS
Weekly 16 (11.9%) 6 (16.2%) 5 (15.6%) 2 (10.5%) 1 (3.9%) 2 (10.0%)
Monthly 67 (50.0%) 18 (48.7%) 12 (37.5%) 14 (73.7%) 13 (50.0%) 10 (50.0%)
Quarterly 36 (26.9%) 12 (32.4%) 10 (31.3%) 3 (15.8%) 8 (30.8%) 3 (15.0%)
Yearly 2 (1.5%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (10.0%)
When patient comes and complains 13 (9.7%) 1 (2.7%) 5 (15.6%) 0 (0.0%) 4 (15.3%) 3 (15.0%)
PREVENTIVE TREATMENT
(n = 118)
Total (n = 118)
n (%)
France (n = 27)
n (%)
Germany (n = 18)
n (%)
Italy (n = 15)
n (%)
Spain (n = 26)
n (%)
UK (n = 32)
n (%)
p value
Evaluation of efficacy NS
Patient perception 89 (75.4%) 21 (77.7%) 12 (66.6%) 10 (66.6%) 19 (73.1%) 27 (84.4%)
Patient diary 69 (58.5%) 17 (62.9%) 14 (77.7%) 10 (66.6%) 16 (61.5%) 12 (37.5%)
Validated scale 15 (13.7%) 2 (7.4%) 2 (11.1%) 2 (13.3%) 6 (23.1%) 3 (9.4%)
Frequency of evaluation of efficacy < 0.050
Weekly 7 (5.9%) 6 (22.2%) 1 (5.5%) 0 (0%) 0 (0%) 0 (0%)
Monthly 47 (39.8%) 9 (33.3%) 5 (27.8%) 8 (53.3%) 13 (50.0%) 12 (37.5%)
Quarterly 48 (40.7%) 12 (44.5%) 9 (50.0%) 7 (46.7%) 9 (34.6%) 11 (34.4%)
Yearly 4 (3.4%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 4 (12.5%)
When patient comes and complains 12 (10.2%) 0 (0%) 3 (16.7%) 0 (0%) 4 (15.4%) 5 (15.6%)
NS non-significant
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therefore, diagnostic uncertainty increases the use of un-
necessary investigations, in agreement with previous
studies [1, 24]. In addition, these results also confirm
that CM is associated with a greater use of healthcare re-
sources in the primary care setting [17].
Forty-six percent of participants used an anamnesis
guide to diagnose CM. Whether a guide is used or not,
awareness of specific warning features in the patient his-
tory to guide diagnosis and management is recom-
mended [9, 10]. Besides, the inclusion of red flags in the
anamnesis guide was independent of the type of guide;
however, more than 85% of the anamnesis guides used
by Spanish and UK GPs included these red flags. The
proper use of red flags would help to identify those pa-
tients where imaging is really needed, but these results
do not seem to be related with a decrease in the use of
imaging techniques to rule out secondary headache dis-
orders. Current guidelines suggest specific warning fea-
tures/red flags that should be detected in the medical
history for differential diagnosis of the headache disor-
ders relevant to primary care [9]. Recently, Phu Do et al.
developed the systematic SNNOOP10, a list of red and
orange flags useful for detecting secondary headache dis-
orders in clinical practice [24].
Effective management of migraine needs to consider
the impact on the patient’s life and lifestyle to establish
the best treatment. In primary care, up to 18 scales are
used to classify or screen for migraine [25]. Although
most of the tools are quick, easy-to-use, self-completed
screening questionnaires, their use is not widely wide-
spread. In this line, we observed that fewer than 50% of
the participants used a validated scale as a screening tool
or during the follow-up. Considering how disabling mi-
graine is, it would be of high interest to enhance relevant
outcomes measurement in clinical routine in these
patients.
The most widely used tool at the first visit was ID-
Migraine (63% of participants). This scale has been vali-
dated in different languages and settings and is common
among GPs [25–28]. Interestingly, 59% of participants
from Italy were using the ID-CM at the first visit, which
perhaps could be explained by the recent translation and
validation of this scale into Italian [29]. The ID-CM scale
is a self-administered tool to help identify individuals
with CM [14]; however, it does not identify other
chronic headache disorders since it does not include ei-
ther warning features to identify secondary headache
disorders, or referral recommendations.
The most used scales by GPs during follow-up in-
cluded ID-CM, MIDAS, and HURT. Despite not being
experts in migraine, the percentage of GPs using the
MIDAS or the HURT scales suggests that the GPs in
this survey had experience in migraine management, as
these scales are not so widespread among GPs.
The anamnesis relies mostly on patient perception of
attack frequency and the evaluation of treatment effi-
cacy, both acute and preventive, reinforcing the import-
ance of patients reported outcomes for migraine
management in the real-life setting [30, 31].
Considering that the prescription of some preventive
treatments (onabotulinum toxin A and CGRP anti-
bodies) for disabling and CM patients is restricted to mi-
graine specialists in most European countries, the low
referral rate reported would support the fact that the
majority of CM patients seem not to receive adequate
preventive treatment. The low use of preventive medica-
tion among migraine patients has been previously re-
ported [15, 18]. In Germany, 83% of participants stated
that the main reason for referring their patients to a spe-
cialist is to give them access to a preventive treatment.
Moreover, preventive treatment would also reduce the
risk of MOH development in CM patients [17]. Now-
adays, a range of effective and well tolerated preventive
drugs for CM exists. Patient access to preventive drugs
remains a challenge in Europe and it is important that
all healthcare professionals managing CM are well in-
formed about all treatment options and the specific pre-
scription conditions in their country.
European and local current guidelines recommend re-
ferral of patients with CM from primary care to specialist
care because diagnosis and management can be difficult
[9, 17, 32]. The low referral rate reported by the GPs could
also be explained by a long wait for patients to see a spe-
cialist, thus giving more pressure on the primary care set-
ting and increasing the visit to the emergency
departments. The assessment of headache disorders pa-
tients in the emergency department setting differs from
the assessment in primary care. A recent retrospective
study analysed migraine management in the emergency
room (ER) to identify deficiencies that could be solved by
a rapid referral to a headache centre. The concordance
analysis between ER diagnosis and tertiary level headache
centre diagnosis showed a significant moderate agreement
for the diagnosis of migraine between triage and headache
centre. Most patients attending ER complaining of head-
ache received the same treatment independently of their
diagnosis; thus, rapid referral to a headache centre is key
to provide a definite diagnosis and appropriate treatment
[33]. In this line, the Spanish Society of Neurology’s Head-
ache Study Group (GECSEN) has issued a series of recom-
mendations constituting a referral protocol to guide
decision-making in patients with headache. This protocol
for action and referral from ER and primary care is aimed
to improve diagnosis and treatment in patients with head-
ache (both primary and secondary) and/or craniofacial
neuralgia [34, 35].
Despite the GP participants having knowledge and ex-
perience of migraine management, the results from this
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survey clearly show that CM patients are undertreated.
Considering that this group of GP’s sees on average 40
patients a day, it would be very challenging to provide
specialist management of CM patients giving an add-
itional explanation to the undertreatment of these pa-
tients. All this suggesting that in a less experienced
primary care setting, the under-treatment of CM pa-
tients could be more extensive. The Vancouver Declar-
ation on Global Headache Patient Advocacy agreed on
the need of adequate training in Headache Medicine of
all HCP and that all patients affected by headache disor-
ders should have reliable access to competent medical
care [36].
Finally, it should be noted that some country differ-
ences may also be explained by differences in the local
healthcare system, the patient’s journey and locally avail-
able guidelines. Nevertheless, the main strength of our
findings derives from the participation of GPs from sev-
eral European countries providing detailed information
regarding the clinical management of CM patients.
This study has some limitations. It is based on a survey
and therefore relies on participants’ recall; thus, the risk
of a selection bias of the participating GPs cannot be ex-
cluded. Moreover, GPs included had clinical experience
with headache disorders suggesting that results regard-
ing under-treatment of CM in primary care could be
even higher than reported.
In summary, this project provides information on
chronic and disabling migraine management in Europe
and suggests the need for guidance in the primary care
setting in order to leverage the diagnosis and treatment
in such patients.
Conclusions
Despite the availability of evidence-based national and
international guidelines, our study emphasizes that there
is a need to improve the diagnosis and management of
migraine in the primary care setting and more specific-
ally the diagnosis, management, and referral, when ap-
propriate, of CM patients.
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